Acquired resistance to mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical models

Resistance to targeted EGFR inhibitors is likely to develop in EGFR mutant lung cancers. Early identification of innate or acquired resistance mechanisms to these agents is essential to direct development of future therapies. We describe the detection of heterogeneous mechanisms of resistance within...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Res
Egile Nagusiak: Eberlein, Catherine A., Stetson, Daniel, Markovets, Aleksandra A., Al-Kadhimi, Katherine J., Lai, Zhongwu, Fisher, Paul R., Meador, Catherine B., Spitzler, Paula, Ichihara, Eiki, Ross, Sarah J., Ahdesmaki, Miika J., Ahmed, Ambar, Ratcliffe, Laura E., Christey O’Brien, Elizabeth L., Barnes, Claire H., Brown, Henry, Smith, Paul D., Dry, Jonathan R., Beran, Garry, Thress, Kenneth S., Dougherty, Brian, Pao, William, Cross, Darren A. E.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2015
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4605607/
https://ncbi.nlm.nih.gov/pubmed/25870145
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-14-3167
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak